1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

HRA Pharma Posts Big Rise As Key Brands Grow Double Digits

 
• By Tom Gallen

Paris-based HRA Pharma reported significant sales gains for its key consumer health brands in 2021, helping to lift group turnover by more than 25%. This is likely to be the last set of results posted by HRA as a standalone company with Perrigo optimistic its proposed acquisition of the firm will soon complete.

SC1807_Market Growth_572387551_1200.jpg
• Source: Shutterstock

France’s HRA Pharma recorded a significant rise in sales in 2021 as demand increased for its biggest consumer health brands.

While the privately-held firm did not disclose a full set of results, it did report a 26% rise in group...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Moberg Has US Ambitions For Novel Nail Fungus Treatment

 
• By Tom Gallen

Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

 
• By Malcolm Spicer

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Complementary Medicine Move Paying Off For Galenica

 
• By Tom Gallen

Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.

Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’

 
• By Malcolm Spicer

PCH lowers full-year guidance even after reaching $100m deal to acquire Canadian sterile ophthalmic manufacturer for its Clears Eyes line troubled by supply slumps for several years. Its $47.5m reported net sales for April-June period were down 6% from a year ago.

More from Business

Over The Counter: Turning Global Ambition Into Local Reality, With Haleon’s Jo Cooper

 
• By David Ridley

HBW Insight speaks to Haleon's UK & Ireland general manager Jo Cooper about how she plans to translate the firm's ambitious global growth strategy to a local context.

Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’

 
• By Malcolm Spicer

PCH lowers full-year guidance even after reaching $100m deal to acquire Canadian sterile ophthalmic manufacturer for its Clears Eyes line troubled by supply slumps for several years. Its $47.5m reported net sales for April-June period were down 6% from a year ago.

Futura Launches Eroxon Strategic Review

 
• By Tom Gallen

Weaker than expected sales of OTC ED treatment Eroxon has led Futura to launch a review of the brand's future direction.